MedTrace Logo

Rivaroxaban 2.5 mg BID and Aspirin for Intermittent Claudication in PAD Patients

NCT04853719 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2024-08-06

No results posted yet for this study

Summary

This trial is evaluating if rivaroxaban 2.5 mg BID and aspirin 100 mg OD compared to aspirin alone improves on intermittent claudication distance in PAD patients.

Conditions

Interventions

DRUG

Rivaroxaban 2.5 Mg Oral Tablet

oral anticoagulants plus antiplatelet agent

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Science Valley Research Institute

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-20
Primary Completion
2022-11-01
Completion
2022-11-01

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04853719 on ClinicalTrials.gov